esogno
g.l. pharma gmbh - eszopiklonas - plėvele dengtos tabletės - 3 mg - eszopiclone
meriofert
ibsa farmaceutici italia srl - menotropinas - milteliai ir tirpiklis injekciniam tirpalui - 75 tv - human menopausal gonadotrophin
meriofert
ibsa farmaceutici italia srl - menotropinas - milteliai ir tirpiklis injekciniam tirpalui - 150 tv - human menopausal gonadotrophin
efmody
diurnal europe b.v. - hidrokortizonas - adrenal hyperplasia, congenital - kortikosteroidų sisteminis naudoti - treatment of congenital adrenal hyperplasia (cah) in adolescents aged 12 years and over and adults.
levosert single-handed inserter
gedeon richter plc - levonorgestrelis - vartojimo į gimdos ertmę sistema - 20 µg/24 val. - plastic iud with progestogen
lutetium (177lu) chloride billev (previously illuzyce)
billev pharma aps - lutetium (177lu) chloride - radionuklidų vaizdavimas - terapiniai radiofarmaciniai preparatai - lutetium (177lu) chloride billev is a radiopharmaceutical precursor, and it is not intended for direct use in patients. it is to be used only for the radiolabelling of carrier molecules that have been specifically developed and authorised for radiolabelling with lutetium (177lu) chloride.
meriofert
ibsa farmaceutici italia srl - menotropinas - milteliai ir tirpiklis injekciniam tirpalui - 900 tv - human menopausal gonadotrophin
klimadynon
bionorica se - kekinių blakėžudžių (cimicifuga racemosa) šakniastiebių sausasis ekstraktas (5-10:1) - plėvele dengtos tabletės - 2,8 mg - cimicifugae rhizoma
vocabria
viiv healthcare b.v. - cabotegavir sodium, cabotegravir - Živ infekcijos - antivirusiniai vaistai sisteminiam naudojimui - vocabria tablets are indicated in combination with rilpivirine tablets for the short-term treatment of human immunodeficiency virus type 1 (hiv-1) infection in adults who are virologically suppressed (hiv-1 rna.
rekambys
janssen-cilag international nv - rilpivirine - Živ infekcijos - antivirusiniai vaistai sisteminiam naudojimui - rekambys is indicated, in combination with cabotegravir injection, for the treatment of human immunodeficiency virus type 1 (hiv 1) infection in adults who are virologically suppressed (hiv-1 rna < 50 copies/ml) on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with, agents of the nnrti and ini class.